Novartis AG (BVMF:N1VS34)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Innovative Medicines Revenue	54.53B	50.32B
Innovative Medicines Revenue Growth	8.38%	12.73%
Revenue (Other)	2.14B	1.41B
Revenue (Total)	56.67B	51.72B
Revenue (Total) Growth	9.57%	10.85%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue (Post-Q2 2023 Reporting)	23.33B	21.15B
United States Revenue (Post-Q2 2023 Reporting) Growth	10.33%	17.75%
Europe Revenue (Post-Q2 2023 Reporting)	16.73B	15.56B
Europe Revenue (Post-Q2 2023 Reporting) Growth	7.53%	3.73%
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)	10.80B	10.02B
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth	7.74%	7.66%
Canada and Latin America Revenue (Post-Q2 2023 Reporting)	3.68B	3.59B
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth	2.28%	13.13%
Revenue (Other)	2.14B	1.41B
Revenue (Total)	56.67B	51.72B
Revenue (Total) Growth	9.57%	10.85%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Cardiovascular, Renal And Metabolic Revenue	8.96B	8.58B
Cardiovascular, Renal And Metabolic Revenue Growth	4.47%	34.21%
Immunology Revenue	10.29B	9.29B
Immunology Revenue Growth	10.76%	19.17%
Neuroscience Revenue	5.99B	4.75B
Neuroscience Revenue Growth	26.17%	30.10%
Oncology Revenue	16.83B	14.30B
Oncology Revenue Growth	17.72%	11.25%
Established Brands Revenue	12.46B	13.40B
Established Brands Revenue Growth	-7.04%	-9.15%
Revenue (Total)	56.67B	51.72B
Revenue (Total) Growth	9.57%	10.85%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Cosentyx Revenue	6.67B	6.14B
Cosentyx Revenue Growth	8.58%	23.31%
Gilenya Revenue	-	552.00M
Gilenya Revenue Growth	-	-40.32%
Entresto Revenue	7.75B	7.82B
Entresto Revenue Growth	-0.95%	29.61%
Tasigna Revenue	1.10B	1.67B
Tasigna Revenue Growth	-33.93%	-9.58%
Lucentis Revenue	643.00M	1.04B
Lucentis Revenue Growth	-38.41%	-29.22%

Updated Dec 31, 2025. Data Source: Fiscal.ai.